Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Assessing efficacy in early-phase cancer prevention trials: the case of oral premalignancy.

Szabo E.

Cancer Prev Res (Phila). 2008 Oct;1(5):312-5. doi: 10.1158/1940-6207.CAPR-08-0171. No abstract available.

2.

Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.

Kelloff GJ, Boone CW, Steele VE, Crowell JA, Lubet R, Sigman CC.

Cancer Res. 1994 Apr 1;54(7 Suppl):2015s-2024s. Review.

3.

Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial".

Stevens RG, Pretlow TP, Hurlstone DP, Giardina C, Rosenberg DW.

Cancer Prev Res (Phila). 2008 Aug;1(3):215-6; author reply 216. doi: 10.1158/1940-6207.CAPR-08-0094. No abstract available.

4.

Design and endpoints of clinical trials in hepatocellular carcinoma.

Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ; Panel of Experts in HCC-Design Clinical Trials..

J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Review.

6.

Primary cancer prevention trials.

Hawk ET, Lippman SM.

Hematol Oncol Clin North Am. 2000 Aug;14(4):809-30. Review.

PMID:
10949775
7.

Implications of recent Australian epidemiological studies for cancer prevention through dietary change.

MacLennan R.

Prog Clin Biol Res. 1990;346:35-44. Review. No abstract available.

PMID:
2197630
8.

Practice and progress in kidney cancer: methodology for novel drug development.

Rini BI, Weinberg V, Small EJ.

J Urol. 2004 Jun;171(6 Pt 1):2115-21. Review.

PMID:
15126769
9.
10.

Chemoprevention of oral cancer: the need for effective biological monitoring.

Pillai MR, Ravi D, Nair MK.

Singapore Dent J. 1997 Aug;22(1):6-12. Review.

PMID:
10597170
12.

An overview of clinical cancer chemoprevention studies with emphasis on positive phase III studies.

Alberts DS, Garcia DJ.

J Nutr. 1995 Mar;125(3 Suppl):692S-697S. Review.

PMID:
7884553
13.
14.

Overview of the randomized phase III trials in non-small cell lung cancer in North America.

Kelly K.

Semin Oncol. 1997 Jun;24(3 Suppl 8):S8-2-S8-5. Review.

PMID:
9207308
15.

Karyometry in the early detection and chemoprevention of intraepithelial lesions.

Ranger-Moore J, Alberts DS, Montironi R, Garcia F, Davis J, Frank D, Brewer M, Mariuzzi GM, Bartels HG, Bartels PH.

Eur J Cancer. 2005 Sep;41(13):1875-88.

PMID:
16087328
16.

Cancer chemoprevention.

Hong WK, Lippman SM.

J Natl Cancer Inst Monogr. 1995;(17):49-53. Review.

PMID:
8573453
17.

[Prevention and early detection of oral mucosa carcinoma].

Stiebitz R, Timmel R.

Osterr Z Stomatol. 1977 Jun;74(6):218-22. German. No abstract available.

PMID:
362338
19.

Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials.

Atalay G, Biganzoli L, Renard F, Paridaens R, Cufer T, Coleman R, Calvert AH, Gamucci T, Minisini A, Therasse P, Piccart MJ; EORTC Breast Cancer and Early Clinical Studies Groups..

Eur J Cancer. 2003 Nov;39(17):2439-49. Review.

PMID:
14602130
20.

Locally advanced non-small cell lung cancer: do we know the questions? A survey of randomized trials from 1966-1993.

Brundage MD, Mackillop WJ.

J Clin Epidemiol. 1996 Feb;49(2):183-92. Review.

PMID:
8606319
Items per page

Supplemental Content

Support Center